AstraZeneca Commits $50 Billion to U.S. Manufacturing and R&D in Drug Pricing Deal
British pharmaceutical giant AstraZeneca has reached a sweeping agreement with the U.S. government to cut prescription drug costs while dramatically expanding its American manufacturing and research footprint. The deal, announced at the White House by CEO Pascal Soriot alongside President Donald Trump, commits the company to invest $50 billion over the next five years in […]
Continue Reading